The National Health Service (NHS) research ethics committee has approved a non-cancer chronic pain clinical trial being rolled out by private health clinic LVL Health.
Phastar, a biometrics contract research organization (CRO) can now officially call its business ‘a force for good’ after it received B Corp certification.
OSP spoke to senior director of clinical trials, Erin Leckrone, and Kathleen Kane, senior manager of clinical operations at Be The Match Biotherapies, to discuss how creating a well-designed and reviewed protocol is critical to a study's overall...
With the FDA issuing guidance on more diversity within clinical trials, it is a subject many companies are being encouraged to focus on, each with their own approach.
CluePoints is continuing to invest in artificial intelligence (AI) and machine learning (ML) they say they want to help clients 'extract every drop of potential from the RBQM-driven interrogation of their own datasets'. It says it recognizes...
Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
A drug to treat a rare cancer that grows where the esophagus and stomach join has been accepted for review by the China National Medical Products Administration (NMPA).
The German and Spanish companies use their relevant expertise in conjunction to provide clients with services spanning from hit generation to pre-clinical development.
Finding a treatment for a skin disease that significantly diminishes the quality of life for those living with it has moved forward to the next phase of trials.
Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator.
A fleet of legal professionals offers advice and perspective on important considerations when harnessing artificial intelligence and real-world evidence.
Impel Pharmaceuticals’ Trudhesa treatment, paired with its Precision Olfactory Delivery system, reportedly shows promise to women suffering from the condition.
The Digital Medicine Society is offering a library of resources to help promote the use of nocturnal scratch as an endpoint for the troubling skin condition.
A representative from the biometric contract research organization explains how taking a ‘patient comes first’ attitude can lead to a range of improvements.
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
A representative from the R&D tech provider offers advice on how to wrangle with a stressful, complicated process for better results and fewer headaches.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
The National Institutes of Health grant to AVM Biotechnology will be used to evaluate a drug to treat non-Hodgkin’s lymphoma combined with standard of care.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
After scientists and reporters raised red flags about a study, Cassava Sciences is being accused of falsifying data in pursuit of an Alzheimer’s treatment.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
An expert from the trial tech firm explains how the 21st Century Cures Act and other recent regulatory advancements can elevate clinical data registries.
With updates to the Guideline for Good Clinical Practice Advancements on the horizon, an industry expert offers some perspective on what might be ahead.
During the World Orphan Drug Congress, a co-founder of the CRO outlined how patient perspective can be vital to better results in rare-disease research.
Bridging the Gap for Clinical Trials is a free competition designed to employ artistic expression to dispel misinformation start positive conversations.
The gathering, convened by patient advocacy group Fight Colorectal Cancer, responded to President Biden’s call to improve screening and treatment options.
The Foundation for Sarcoidosis Research hosted more than 50 agency leaders in a session that addressed patient concerns in research, care, and diagnosis.
A pediatric clinical trial expert from the CRO discusses the unique challenges involved in designing a study when the patients involved are little ones.
Taking place July 20, the Decentralized Trial Technology webinar will share insights and experiences from a group of knowledgeable virtual trial experts.
A leader from healthcare commercial intelligence company Definitive Healthcare discusses the rise of precision medicine and the benefits the field can yield.
In this second of a two-part series, a leader from the CRO discusses the types of technologies supporting DCTs and what might lie on the horizon for the field.
Biotech supply chains face an uncertain future in 2022 and beyond: up against myriad challenges ranging from future pandemic outbreaks to geopolitical tensions – and, indeed, unforeseen threats. Communication and collaboration between policymakers and...
The latest indepth report from the AI-centric analytics provider reveals nearly half of US cancer clinical studies enroll no Latino patient participants.
In this first of a two-part series, an expert discusses various factors behind the DCT format’s rapid rise and likely longevity in the drug development arena.
The academic research center has adopted the life science technology company’s cloud-based platform for cancer research, drug discovery, and clinical trials.
England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
On July 20, a collection of noted industry experts will lead a lively discussion on the rapid evolution of DCTs, and what advances might be on the horizon.
The past two years have been full of shifts and shakes in the drug development field, but the change at Outsourcing-Pharma is easy and one for the better.
An expert from the decentralized trial solutions company shares how eCOA and ePRO can be useful tools that improve the collection and quality of such data.
